Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1474 • ACR Convergence 2022
Quinolinic Acid, a Kynurenine/Tryptophan Pathway Metabolite, Correlates with Abnormalities in Brain Structure and Function in SLE
Erik Anderson, Chris Tang, An Vo, Cynthia Aranow, Bruce Volpe, Betty Diamond and Meggan Mackay, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Stimulation of the kynurenine/tryptophan pathway by interferons alpha and gamma, both known contributors to SLE pathogenesis, leads to a potentially neurotoxic imbalance of pathway…
Abstract Number: 1595 • ACR Convergence 2022
Association of Sustained Lupus Low Disease Activity State with Improved Outcomes in SLE: A Multinational Prospective Cohort Study
Vera Golder¹, Rangi Kandane-Rathnayake¹, Ning Li¹, Worawit Louthrenoo², Yi-Hsing Chen³, Jiacai Cho⁴, Aisha Lateef⁵, Laniyati Hamijoyo⁶, Luo Shue Fen⁷, Yeong-Jian Wu⁷, Sandra Navarra⁸, Leonid Zamora⁸, Zhanguo Li⁹, An Yuan¹⁰, Sargunan Sockalingam¹¹, Yasuhiro Katsumata¹², Masayoshi Harigai¹², Yanjie Hao¹³, Zhouli Zhang¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathryn Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Yoshiya Tanaka²⁸, Chak Sing²⁹, Alberta Hoi³⁰, Mandana Nikpour³¹ and Eric Morand³², ¹Monash University, Clayton, Australia, ²Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴National University Health System (NUHS), Singapore, Singapore, ⁵National University Hospital, Singapore, Singapore, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁸University of Santo Tomas, Manila, Philippines, ⁹Peking University People's Hospital, Beijing, China, ¹⁰Peking University Health Science Center, Beijing, China, ¹¹University of Malaya, Kuala Lumpur, Kuala Lumpur, Malaysia, ¹²Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹³The University of Melbourne, Melbourne, Australia, ¹⁴Peking University First Hospital, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University School of Medicine, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹The University of Hong Kong, Pok Fu Lam, Hong Kong, ³⁰Monash Health, Melbourne, Australia, ³¹The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Since the initial prospective validation of the Lupus Low Disease Activity State (LLDAS), this treat-to-target endpoint has been studied in numerous other cohorts, with…
Abstract Number: 1709 • ACR Convergence 2022
Role of Corneal Langerhans Dendritic Cells in Lupus Keratitis
Ram Singh¹ and Angel Gutierrez², ¹UCLA David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA
Background/Purpose: Patients with lupus and other systemic autoimmune diseases develop ocular surface inflammation that is sometimes severe and debilitating. Pathogenesis of autoimmune keratitis remains unclear.…
Abstract Number: 1779 • ACR Convergence 2022
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao², Jessica Williams², S. Sam Lim¹ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic may have a sustained impact on systemic lupus erythematosus (SLE) patients in multiple ways. In a large predominantly Black SLE cohort,…
Abstract Number: 2061 • ACR Convergence 2022
Impact of Time to Remission, Flares and Exposure to Immunosuppressives on the Development of Advanced Chronic Kidney Disease (Stage IV or Worse) in Lupus Nephritis
Dafna Gladman¹, KONSTANTINOS TSELIOS², Jiandong Su³ and Murray Urowitz⁴, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years.…
Abstract Number: 2079 • ACR Convergence 2022
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
Wils Nielsen¹, Vibeke Strand², Lee S Simon³, Julian Thumboo⁴, Marta Mosca⁵, Martin Aringer⁶, Sindu Johnson⁷, Aaron Drucker⁷, Eric Morand⁸, Ian N. Bruce⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³SDG LLC, West Newton, MA, ⁴Singapore General Hospital, Bukit Merah, Singapore, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁶University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁷University of Toronto, Toronto, ON, Canada, ⁸Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The development of a Core Outcome domain Set (COS) can aid research communication and standardizing measurement tools of SLE. A COS captures SLE facets…
Abstract Number: 2099 • ACR Convergence 2022
Drug Repurposing for Treating Lupus Nephritis Based on Transcriptome Profiling and Autoimmunity-Related Serological Markers
Ioannis Parodis¹, Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme² and Guillermo Barturen², ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: LN is one of the most severe organ manifestations of SLE and constitutes an important cause of morbidity and death among patients with SLE…
Abstract Number: 2223 • ACR Convergence 2022
Transcriptome Profiling and Autoimmunity-related Serological Markers Identify Tumour Protein P53 and Complement C3a Receptor 1 as Drug Targets in Neuropsychiatric Systemic Lupus Erythematosus
Julius Lindblom¹, Daniel Toro-Domínguez², Elena Carnero-Montoro², Maria Orietta Borghi³, Jessica Castillo⁴, Ellen Iacobaeus¹, Yvonne Enman⁵, Chandra Mohan⁴, Marta Alarcon-Riquelme², Guillermo Barturen² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ³Università degli Studi di Milano and Istituto Auxologico Italiano, Milano, Italy, ⁴University of Houston, Houston, TX, ⁵Karolinska Institutet, Sundbyberg, Sweden
Background/Purpose: Involvement of the nervous system is a common but poorly understood manifestation of SLE, termed NPSLE. Although studies have reported varying prevalence estimates (Unterman…
Abstract Number: 0061 • ACR Convergence 2022
Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry
thomas Ituarte¹, Jing Li², Julia Kay³, Zara Izadi⁴, Jinoos Yazdany³ and Gabriela Schmajuk⁵, ¹UCSF, San Francisco, ²University of California, San Francisco, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: Diagnostic uncertainty is a common problem faced by rheumatologists. Even among patients under the care of a rheumatologist, patients may have one rheumatic illness…
Abstract Number: 0114 • ACR Convergence 2022
Addressing Healthcare Disparities Through Implementation of a Medical Student-Based Patient Navigator Program
Grace Shadid¹, Zaid Nakadar¹, Miar Elaskandrany¹, Huchong Cai¹, Alejandra Moncayo¹, Ayten Sergios¹, Marcos Vargas¹, Jeremy Wilson¹, Naureen Kabani², Olga Dvorkina¹ and Ellen M. Ginzler², ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY
Background/Purpose: African American, Afro-Caribbean, and Hispanic patients diagnosed with rheumatic diseases such as systemic lupus erythematosus (SLE) exhibit more severe disease manifestations compared to white…
Abstract Number: 0327 • ACR Convergence 2022
SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus
Ai Li Yeo¹, Rangi Kandane-Rathnayake², Rachel Koelmeyer³, Vera Golder², Worawit Louthrenoo⁴, Yi-Hsin Chen⁵, Jiacai Cho⁶, Aisha Lateef⁷, Laniyati Hamijoyo⁸, Luo Shue Fen⁹, Yeong-Jian Wu⁹, Sandra Navarra¹⁰, Leonid Zamora¹¹, Zhanguo Li¹², An Yuan¹³, Sargunan Sockalingam¹⁴, Yasuhiro Katsumata¹⁵, Masayoshi Harigai¹⁵, Yanjie Hao¹⁶, Zhouli Zhang¹⁷, Duminda Basnayake¹⁸, Madelynn Chan¹⁹, Jun Kikuchi²⁰, Tsutomu Takeuchi²¹, Sang-Cheol Bae²², Shereen Oon²³, Sean O'Neill²⁴, Fiona Goldblatt²⁵, Kathy Gibson²⁴, Kristine Ng²⁶, Hui Nee Annie Law²⁷, Nicole Tugnet²⁸, Sunil Kumar²⁹, Cherica Tee³⁰, Michael Tee³⁰, Yoshiya Tanaka³¹, Naoaki Ohkubo³¹, Chak Sing³², Mandana Nikpour³³, Alberta Hoi³⁴, Michelle Leech³ and Eric Morand³⁵, ¹Monash Health and Monash University, Melbourne, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia, ⁴Chiang Mai University, Chiang Mai, Thailand, ⁵Taichung Veterans General Hospital, Taichung, Taiwan, ⁶National University Health System (NUHS), Singapore, Singapore, ⁷National University Hospital, Singapore, Singapore, ⁸Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ¹⁰University of Santo Tomas, Manila, Philippines, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China, ¹³Peking University Health Science Center, Beijing, China, ¹⁴University of Malaya, Kuala Lumpur, Malaysia, ¹⁵Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁶The University of Melbourne, Melbourne, Australia, ¹⁷Peking University First Hospital, Beijing, China, ¹⁸Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁹Tan Tock Seng Hospital, Singapore, Singapore, ²⁰Keio University, Tokyo, Japan, ²¹Keio University and Saitama Medical University, Tokyo, Japan, ²²Hanyang University Medical Center, Seoul, Republic of Korea, ²³St Vincent's Hospital, Fitzroy, Australia, ²⁴Liverpool Hospital, Sydney, Australia, ²⁵Flinders Medical Centre, Adelaide, Australia, ²⁶North Shore Hospital, Auckland, New Zealand, ²⁷Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁸Greenlane Clinical Centre, Auckland, New Zealand, ²⁹Middlemore Hospital, Auckland, New Zealand, ³⁰University of the Philippines, Quezon City, Philippines, ³¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ³²The University of Hong Kong, Pok Fu Lam, Hong Kong, ³³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³⁴Monash Health, Melbourne, Australia, ³⁵Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia
Background/Purpose: Disease monitoring in systemic lupus erythematosus (SLE) includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the…
Abstract Number: 0345 • ACR Convergence 2022
Association Between Cumulated Hydroxychloroquine in Systemic Lupus Erythematosus and Development of Cardiac Conduction Alterations: A Multiple Logistic Regression Analysis
Alba Herrero-Morant¹, Jon Zubiaur-Zamacola², Adrián Margarida-De Castro², Raquel Pérez-Barquín², Miguel Ángel González-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE). It may cause cardiac alterations which includes short term arrhythmic events (via…
Abstract Number: 0367 • ACR Convergence 2022
Comparative Risk of COVID-19 Among Patients with Systemic Lupus Erythematosus According to Immunosuppressant Use
April Jorge¹, Baijun Zhou¹, yuqing zhang² and Hyon Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA, ³MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Patients with SLE are at increased risk of COVID-19 and its severe outcomes, in part due to the use of immunosuppressants. We sought to…
Abstract Number: 0632 • ACR Convergence 2022
Single-cell Multiomic Profiling Differentiates Ancestral B Cell Pathologies Contributing to Lupus Disease Activity
Kevin Thomas, Miles Smith, Samantha Slight-Webb, Susan Macwana, Joseph Kheir, Carla J. Guthridge, Wade deJager, Christian Wright, Bolanle Adebayo, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Genetic ancestry impacts SLE prevalence, clinical presentation, and treatment response; however, the molecular underpinnings of this disparity remain poorly understood. Recent findings demonstrate that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].